Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 5, 2026Cancer Research

EMT-like Reprogramming Drives Drug-Tolerant Persister Cell Plasticity in Mantle Cell Lymphoma

View Full Paper
Ask AI
Bookmark
Share

Authors

WWWei WangNational Natural Science Foundation of ChinaYLYang LiuThe University of Texas MD Anderson Cancer CenterHLHeng‐Huan LeeThe University of Texas MD Anderson Cancer Center

Discussion

Loading...

Member takes

Implication

This research finds that EMT-like processes contribute to therapy resistance in mantle cell lymphoma, suggesting new treatment strategies.

Key Points

  • The study aims to explore whether EMT-like reprogramming influences drug resistance in mantle cell lymphoma through metabolic changes.
  • Established a drug-tolerant persister cell model using pirtobrutinib.
  • Utilized integrated RNA sequencing and ultra-high-resolution metabolomics for analysis.
  • Analyzed cellular transformation under therapeutic pressure and during drug withdrawal.
  • DTP cells in mantle cell lymphoma undergo significant morphological and metabolic changes.
  • A metabolic switch enhances cellular plasticity and supports therapy resistance.
  • Targeting ribosome biogenesis can restore therapy sensitivity by disrupting drug tolerance.

Cite This Study

Wang et al. (2026) studied this question.

synapsesocial.com/papers/69d1fc4fa79560c99a0a1eefhttps://doi.org/10.1158/1538-7445.am2026-392
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Abstract A018: EMT-like reprogramming defines drug-tolerant persister cell plasticity in mantle cell lymphoma2026
  2. 2The switch of TCA cycle mode determines the fate of pirtobrutinib-tolerant persister cells2025 · 1 citations
  3. 3Abstract PO-025: Identifying tissue-specific drivers of immune evasion in Mantle Cell Lymphoma at single cell level2024
  4. 4Abstract LT07: EPIGENETIC VULNERABILITIES DRIVE SURVIVAL OF DRUG-TOLERANT PERSISTERS AND REVEAL THERAPEUTIC OPPORTUNITIES IN AML2026
  5. 5Abstract 7047: Characterization of TKI-induced drug-tolerant persister cells from patient-derived cell lines.2026